Analysts See $-0.98 EPS for KemPharm, Inc. (KMPH)

July 14, 2018 - By Mark Mitchell

KemPharm, Inc. (NASDAQ:KMPH) Logo

Analysts expect KemPharm, Inc. (NASDAQ:KMPH) to report $-0.98 EPS on August, 9.They anticipate $0.54 EPS change or 122.73 % from last quarter’s $-0.44 EPS. After having $-1.11 EPS previously, KemPharm, Inc.’s analysts see -11.71 % EPS growth. The stock decreased 6.36% or $0.35 during the last trading session, reaching $5.15. About 322,172 shares traded or 212.89% up from the average. KemPharm, Inc. (NASDAQ:KMPH) has risen 51.19% since July 14, 2017 and is uptrending. It has outperformed by 38.62% the S&P500.

KemPharm, Inc. (NASDAQ:KMPH) Ratings Coverage

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 7 analyst reports since January 16, 2018 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Friday, February 23. RBC Capital Markets maintained the shares of KMPH in report on Tuesday, January 16 with “Buy” rating. The firm has “Buy” rating given on Monday, April 2 by Oppenheimer. The firm earned “Buy” rating on Monday, February 26 by Canaccord Genuity. The company was maintained on Monday, April 2 by Roth Capital. On Sunday, February 25 the stock rating was maintained by Oppenheimer with “Buy”.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $81.16 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

More important recent KemPharm, Inc. (NASDAQ:KMPH) news were published by: Benzinga.com which released: “20 Stocks Moving In Monday’s Pre-Market Session” on July 09, 2018, also Benzinga.com published article titled: “41 Biggest Movers From Yesterday”, Seekingalpha.com published: “Evaluating KemPharm’s KP415, Part 3: KP415’s Potential” on July 03, 2018. More interesting news about KemPharm, Inc. (NASDAQ:KMPH) was released by: Benzinga.com and their article: “KemPharm’s ADHD Candidate Meets Efficacy, Safety Trial Endpoints” with publication date: July 09, 2018.

KemPharm, Inc. (NASDAQ:KMPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.